Fig. 5: Combination with CP-673451 improved anti-tumour effect of temozolomide in a subcutaneous GBM mouse model.
From: PDGF-R inhibition induces glioblastoma cell differentiation via DUSP1/p38MAPK signalling
A Volumes of U87 GBM cell subcutaneous xenograft tumours from athymic nude mice were measured after 3 weeks of treatment with TMZ (25 mg/kg), CP-673451 (40 mg/kg) or combination treatment. The mean ± SEM is shown. B Image of the tumours extracted from mice after 3 weeks of treatment separated into each treatment group. C Ki67 immunohistochemistry staining was performed on tumour tissue post treatment and the number of cells stained per field quantified. The mean ± SD is shown *p ≤ 0.05, **p ≤ 0.01 and ***p ≤ 0.001 (two-tailed t-test).
